Clinical review: Clinical management of new oral anticoagulants: A structured review with emphasis on the reversal of bleeding complications

Critical Care

Volumn 17, Issue 3, 2013, Pages

  Lazo Langner, Alejandro ^a   Lang, Eddy S ^b   Douketis, James ^c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; COFACT; DABIGATRAN; DABIGATRAN ETEXILATE; KANOKAD; PROTHROMBINASE COMPLEX CONCENTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; UNCLASSIFIED DRUG; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; THIOPHENE DERIVATIVE;

BLEEDING; DEEP VEIN THROMBOSIS; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG USE; HEART ATRIUM FIBRILLATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTERNATIONAL NORMALIZED RATIO; NONHUMAN; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; SYSTEMATIC REVIEW; THROMBIN TIME; VENOUS THROMBOEMBOLISM; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; DISEASE MANAGEMENT; HEMORRHAGE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; DISEASE MANAGEMENT; HEMORRHAGE; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDONES; THIOPHENES;

EID: 84879555624     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc12592     Document Type: Review

References (69)

1. U.S. Food and Drug Administration FDA News release. FDA expands use of Xarelto to treat, reduce recurrence of blood clots. U.S. Food and Drug Administration., http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm326654.htm
2. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007, 64:292-303. 10.1111/j.1365-2125.2007.02899.x, 2000643, 17506785.
3. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005, 78:412-421. 10.1016/j.clpt.2005.06.011, 16198660.
4. The Thrombosis Interest Group of Canada homepage. , http://www.tigc.org/
5. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008, 358:2127-2137. 10.1056/NEJMoa0707534, 18480205.
6. Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, Sundaram V, McMahon D, Olkin I, McDonald KM, Owens DK, Stafford RS. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med 2011, 154:529-540. 10.7326/0003-4819-154-8-201104190-00004, 21502651.
7. Dutton RP, Parr M, Tortella BJ, Champion HR, Bernard GR, Boffard K, Bouillon B, Croce MA, Dimsits J, Holcomb JB, Leppaniemi A, Vincent JL, Hauser CJ, CONTROL Study Group Recombinant activated factor VII safety in trauma patients: results from the CONTROL trial. J Trauma 2011, 71:12-19. 10.1097/TA.0b013e31821a42cf, 21610529, CONTROL Study Group.
8. Majeed A, Eelde A, Agren A, Schulman S, Holmstrom M. Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy. Thromb Res 2012, 129:146-151. 10.1016/j.thromres.2011.07.024, 21807399.
9. Hsia CC, Chin-Yee IH, McAlister VC. Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. Ann Surg 2008, 248:61-68. 10.1097/SLA.0b013e318176c4ec, 18580208.
10. Dentali F, Marchesi C, Pierfranceschi MG, Crowther M, Garcia D, Hylek E, Witt DM, Clark NP, Squizzato A, Imberti D, Ageno W. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 2011, 106:429-438. 10.1160/TH11-01-0052, 21800002.
11. Lu G, Luan P, Hollenbach SJ, Abe K, Deguzman FR, Siu G, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U. Reconstructed recombinant factor Xa as an antidote to reverse anticoagulation by factor Xa inhibitors. J Thromb Haemost 2009, (7). Abstract OC-TH-107.
12. Lu G, Deguzman FR, Karbarz MJ, Hollenbach SJ, Conley PB, Hutchaleelaha A, Sinha U. Reversal of rivaroxaban mediated anticoagulation in animal models by a recombinant antidote protein (r-Antidote, PRT064445). Eur Heart J 2011, 32. Abstract 3715.
13. Van Ryn J, Litzenburger T, Waterman A, Canada K, Hauel N, Sarko C, Kroe-Barrett R, Singh S, Park J. An antibody selective to dabigatran safely neutralizes both dabigatran-induced anticoagulant and bleeding activity in in vitro and in vivo models. J Thromb Haemost 2011, 9:110. Abstract P-MO-166.
14. Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 2010, 152:578-589. 10.7326/0003-4819-152-9-201005040-00008, 20439576.
15. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003, 139:893-900. 10.7326/0003-4819-139-11-200312020-00007, 14644891.
16. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKET AF Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891. 10.1056/NEJMoa1009638, 21830957, ROCKET AF Investigators.
17. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 -an oral, direct factor Xa inhibitor- after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005, 61:873-880. 10.1007/s00228-005-0043-5, 16328318.
18. Kubitza D, Becka M, Mueck W, Halabi A, Maatouk H, Klause N, Lufft V, Wand DD, Philipp T, Bruck H. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2010, 70:703-712. 10.1111/j.1365-2125.2010.03753.x, 2997310, 21039764.
19. Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010, 49:259-268. 10.2165/11318170-000000000-00000, 20214409.
20. Van Ryn J, Neubauer M, Flieg R, Krause B, Storr M, Hauel N, Priepke H, Clemens A. Successful removal of dabigatran in flowing blood with an activated charcoal hemoperfusion column in an in vitro test system. Pathophysiol Haemost Thromb 2010, 37. Abstract P 485.
21. Lindahl TL, Baghaei F, Blixter IF, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Hillarp A, Expert Group on Coagulation of the External Quality Assurance in Laboratory Medicine in Sweden Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011, 105:371-378. Expert Group on Coagulation of the External Quality Assurance in Laboratory Medicine in Sweden.
22. Majeed A, Hwang H, Bruggink ED, Connolly S, Eikelboom JW, Ezekowitz M, Wallentin L, Yusuf S, Schulman S. Management and outcomes of major bleeding on dabigatran or warfarin. Blood 2012, 120. Abstract 19.
23. Chan HHW, Atkinson HM, Goncharenko M, Berry LR, Chan AKC. Reversal of dabigatran using recombinant activated factor vii and activated prothrombin complex concentrates in thromboelastography assay. J Thromb Haemost 2011, 9:576-577. Abstract P-WE-180.
24. Eerenberg ES, Sijpkens MK, Kamphuisen PW, Meijers JCM, Levi M. Prothrombin complex concentrate reverses the anticoagulant eff ect of rivaroxaban in healthy volunteers. Blood 2010, 116. Abstract 1094.
25. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JCM, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, cross-over study in healthy subjects. J Thromb Haemost 2011, 9:657. Abstract P-WE-435.
26. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011, 124:1573-1579. 10.1161/CIRCULATIONAHA.111.029017, 21900088.
27. Godier A, Miclot A, Le BB, Durand M, Lecompte T, Samama CM. Evaluation of prothrombin complex concentrate, recombinant activated factor VII and fibrinogen concentrate to reverse rivaroxaban in a rabbit model of bleeding and thrombosis. Eur J Anaesthesiol 2011, 28:87. Abstract 6AP3-8.
28. Godier A, Miclot A, Le BB, Durand M, Emmerich J, Fischer AM, Lecompte T, Samama CM. Evaluation of prothrombin complex concentrate, recombinant activated factor VII and fibrinogen concentrate to reverse rivaroxaban in a rabbit model. J Thromb Haemost 2011, 9:388. Abstract P-TU-253.
29. Godier A, Miclot A, Le BB, Durand M, Fischer A-M, Emmerich J, Marchand-Leroux C, Lecompte T, Samama C-M. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012, 116:94-102. 10.1097/ALN.0b013e318238c036, 22042412.
30. Gruber A, Marzec UM, Buetehorn U, Hanson SR, Perzborn E. Activated factor VII and activated prothrombin complex for reversal of the antihaemostatic effects of rivaroxaban in primates. Br J Haematol 2009, 145. Abstract 80.
31. Gruber A, Marzec UM, Buetehorn U, Hanson S, Perzborn E. Reversal of the antihaemostatic effects of rivaroxaban by activated factor VII and activated prothrombin complex in primates. Haematologica 2009, 94. June Abstract 0449.
32. Keller MK, Langer E, Ziemer S, Von HC. RIVACAPT (RIVAroxaban Coagulation Antagonisation Pilot Trial). Hamostaseologie 2012, 32:A13. Abstract ED10-7.
33. Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012, 108:217-224. 10.1160/TH12-03-0179, 22627883.
34. Martin A-C, Le BB, Lecompte T, Dizier B, Emmerich J, Fischer A-M, Samama C-M, Godier A. Evaluation of prothrombin complex concentrate, recombinant activated factor VII and fibrinogen concentrate to reverse apixaban in a rabbit model. Cardiovasc Res 2012, 93:S73. Abstract P364.
35. Martin A-C, Le-Bonniec B, Lecompte T, Fischer A-M, Emmerich J, Samama C-M, Godier A, Val De GH. Evaluation of recombinant activated factor VII, prothrombin complex concentrate and fibrinogen concentrate to reverse apixaban in a rabbit model. J Am Coll Cardiol 2012, 59:E573.
36. Martin A-C, Le-Bonniec B, Lecompte T, Fischer A-M, Emmerich J, Samama C-M, Godier A. Evaluation of recombinant activated factor VII, prothrombin complex concentrate and fibrinogen concentrate to reverse apixaban in a rabbit model. Eur Heart J 2012, 33:496. Abstract 2963.
37. Olesen JB, Christiansen K, Ingerslev J, Sorensen B, Hvas A. Haemostatic response to in vitro addition of recombinant factor Vila, prothrombin complex concentrate, or concentrate of Factor IX/X in blood spiked with a direct Xa inhibitor. J Thromb Haemost 2009, 7. Abstract PP-MO-386.
38. Perzborn E, Trabandt A, Selbach K, Tinel H. Prothrombin complex concentrate reverses the effects of high-dose rivaroxaban in rats. Hamostaseologie 2010, 30:A103. Abstract P16-01.
39. Perzborn E, Trabandt A, Selbach K, Tinel H. Prothrombin complex concentrate reverses the effects of high-dose rivaroxaban in rats. Pathophysiol Haemost Thromb 2010, 37. Abstract OC 251.
40. Pragst I, Zeitler SH, Doerr B, Kaspereit FJ, Herzog E, Dickneite G, van Ryn J. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost 2012, 10:1841-1848. 10.1111/j.1538-7836.2012.04859.x, 22812619.
41. Van Ryn J, Ruehl D, Priepke H, Hauel N, Wienen W. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate. Haematologica 2008, 93. Abstract 0370.
42. Van Ryn J, Neubauer M, Flieg R, Krause B, Storr M, Hauel N, Priepke H, Clemens A. Successful removal of dabigatran in flowing blood with an activated charcoal hemoperfusion column in an in vitro test system. Haematologica 2010, 95:293. Abstract 0700, 10.3324/haematol.2009.013318, 2817033, 20139392.
43. Van Ryn J, Dorr B, Kaspereit F, Krege W, Zeitler S, Pragst I. Beriplex P/N reverses bleeding in an acute renal injury model after dabigatran overdose in rabbits. Pathophysiol Haemost Thromb 2010, 37. Abstract P 486.
44. Van Ryn J, Schurer J, Kink-Eiband M, Clemens A. The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation. Blood 2011, 118. Abstract 2316.
45. Van Ryn J, Litzenburger T, Waterman A, Canada K, Hauel N, Sarko C, Kroe-Barrett R, Singh S, Park J. Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models. J Am Coll Cardiol 2011, 57:E1130.
46. Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, Bendszus M, Heiland S, van Ryn J, Veltkamp R. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011, 42:3594-3599. 10.1161/STROKEAHA.111.624650, 21998060.
47. Lloyd J, Feldman P, Ryan L. In vitro reversal of the direct Xa inhibitor rivaroxaban using high-purity factor × concentrate (factor X). Haemophilia 2012, 18:33. Abstract PO-TU-033.
48. Toth J, Gandolfi R, Van Ryn J, Dursema H, Isler J, Coble K, Burke J, Lalovic B, Olson S. Reversal of dabigatran's anticoagulant activity in the monkey by a specific antidote and pharmacokinetic and pharmacodynamic modeling. Blood 2012, 120. Abstract 22.
49. Galan A, Arellano-Rodrigo E, Sanz V, Molina P, Reverter JC, Carne X, Villalta J, Tassies D, Diaz-Ricart M, Escolar G. Reversal of the antithrombotic action of rivaroxaban and dabigatran: a clinical study in healthy volunteers. Blood 2012, 120. Abstract 2261.
50. Escolar G, Arellano-Rodrigo E, Reverter JC, Villalta J, Sanz V, Molina P, Diaz-Ricart M, Galan A. Coagulation factor concentrates restore alterations in hemostasis induced by a high dose of apixaban: studies in vitro with circulating human blood. Blood 2012, 120. Abstract 2263.
51. Lange J, Thiel C, Thiel K, Klingert W, Klingert K, Konigsrainer A, Formella S, Clemens A, Van Ryn J, Schenk M. Acceleration of dabigatran elimination by activated charcoal perfusion and hemodialysis in a pig model. Blood 2012, 120. Abstract 2272.
52. Pillitteri D, Pilgrimm-Thorp A, Krause M, Scholz T, Schwerdtfeger R, Behrendt T, Kirchmaier C. Antidotal effects of non-specific reversal agents on anticoagulant-induced inhibition of thrombin generation. Blood 2012, 120. Abstract 2273.
53. Hollenbach SJ, Lu G, Tan S, Lee G, Hutchaleelaha A, Inagaki M, Sinha U. PRT064445 but not recombinant Fviia reverses rivaroxaban induced anticoagulation as measured by reduction in blood loss in a rabbit liver laceration model. Blood 2012, 120. Abstract 3414.
54. Van Ryn J, Litzenburger T, Gan G, Coble K, Schurer J. In vitro characterization, pharmacokinetics and reversal of supratherapeutic doses of dabigatran-induced bleeding in rats by a specific antibody fragment antidote to dabigatran. Blood 2012, 120. Abstract 3418.
55. Hoffman M, Volovyk Z, Monroe D. Partial reversal of dabigatran effect by a prothrombin complex concentrate in a model of thrombin generation. Blood 2012, 120. Abstract 3420.
56. Van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010, 103:1116-1127. 10.1160/TH09-11-0758, 20352166.
57. Bayer Inc Xarelto (Rivaroxaban) Product Monograph. 2012, Toronto, Ontario, Bayer Inc.
58. Boehringer Ingelheim Pradaxa (Dabigatran Etexilate) Product Monograph. 2012, Burlington, Ontario, Boehringer Ingelheim.
59. Pfizer Inc, Bristol-Myers Squibb Eliquis (apixaban) Product Monograph. 2011, Kirkland, Quebec; Montreal, Quebec, Pfizer Inc, Bristol-Myers Squibb.
60. Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, Reeves RA, Lacreta F. Apixaban, an oral, direct factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 2013, 75:476-487. 10.1111/j.1365-2125.2012.04369.x, 3558798, 22759198.
61. Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, Pinto D, Chen S, Bonacorsi S, Wong PC, Zhang D. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009, 37:74-81. 10.1124/dmd.108.023143, 18832478.
62. Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Lindahl TL. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011, 9:133-139. 10.1111/j.1538-7836.2010.04098.x, 20946166.
63. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogne JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012, 107:985-997. 10.1160/TH11-11-0804, 22438031.
64. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012, 23:138-143. 10.1097/MBC.0b013e32834f1b0c, 22227958.
65. DeRemer CE, Gujral JS, Thornton JW, Sorrentino RA. Dabigatran falsely elevates point of care international normalized ratio results. Am J Med 2011, 124:e5-e6.
66. Baruch L, Sherman O. Potential inaccuracy of point-of-care INR in dabigatran-treated patients. Ann Pharmacother 2011, 45:e40. 10.1345/aph.1Q105, 21712509.
67. Freyburger G, Macouillard G, Labrouche S, Sztark F. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 2011, 127:457-465. 10.1016/j.thromres.2011.01.001, 21277622.
68. Samama MM, Martinoli JL, LeFlem L, Guinet C, Depasse F, Perzborn E. Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor. Thromb Haemost 2010, 103:815-825. 10.1160/TH09-03-0176, 20135059.
69. Wong PC, Crain EJ, Watson CA, Xin B. Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits. J Thromb Haemost 2009, 7:1313-1320. 10.1111/j.1538-7836.2009.03503.x, 19500242.